PE20242180A1 - Conjugados peptidicos de inhibidores de tubulina peptidica como agentes terapeuticos - Google Patents
Conjugados peptidicos de inhibidores de tubulina peptidica como agentes terapeuticosInfo
- Publication number
- PE20242180A1 PE20242180A1 PE2024001102A PE2024001102A PE20242180A1 PE 20242180 A1 PE20242180 A1 PE 20242180A1 PE 2024001102 A PE2024001102 A PE 2024001102A PE 2024001102 A PE2024001102 A PE 2024001102A PE 20242180 A1 PE20242180 A1 PE 20242180A1
- Authority
- PE
- Peru
- Prior art keywords
- peptide
- therapeutic agents
- tubulin inhibitors
- conjugates
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280409P | 2021-11-17 | 2021-11-17 | |
| PCT/US2022/079973 WO2023091957A1 (en) | 2021-11-17 | 2022-11-16 | Peptide conjugates of peptidic tubulin inhibitors as therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20242180A1 true PE20242180A1 (es) | 2024-11-07 |
Family
ID=84799580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001102A PE20242180A1 (es) | 2021-11-17 | 2022-11-16 | Conjugados peptidicos de inhibidores de tubulina peptidica como agentes terapeuticos |
Country Status (14)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| BR112022000297A2 (pt) | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078816A2 (en) * | 2005-01-18 | 2006-07-27 | The Board Of Governors For Higher Education | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide |
| EP2927227A4 (en) * | 2013-01-03 | 2015-12-30 | Celltrion Inc | ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH |
| WO2018023098A1 (en) * | 2016-07-29 | 2018-02-01 | Memorial Sloan Kettering Cancer Center | Radiolabeled ligands for targeted pet/spect imaging and methods of their use |
| MX2022000449A (es) * | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| BR112022000297A2 (pt) * | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
-
2022
- 2022-11-16 AU AU2022390891A patent/AU2022390891A1/en active Pending
- 2022-11-16 EP EP22836006.1A patent/EP4433095A1/en active Pending
- 2022-11-16 CN CN202280089024.1A patent/CN118574642A/zh active Pending
- 2022-11-16 US US18/056,117 patent/US20230416331A1/en active Pending
- 2022-11-16 MX MX2024005938A patent/MX2024005938A/es unknown
- 2022-11-16 CA CA3243300A patent/CA3243300A1/en active Pending
- 2022-11-16 WO PCT/US2022/079973 patent/WO2023091957A1/en not_active Ceased
- 2022-11-16 JP JP2024529599A patent/JP2024542212A/ja active Pending
- 2022-11-16 TW TW111143837A patent/TW202330015A/zh unknown
- 2022-11-16 IL IL312884A patent/IL312884A/en unknown
- 2022-11-16 PE PE2024001102A patent/PE20242180A1/es unknown
- 2022-11-16 KR KR1020247020055A patent/KR20240130157A/ko active Pending
-
2024
- 2024-05-16 CL CL2024001486A patent/CL2024001486A1/es unknown
- 2024-06-13 CO CONC2024/0007413A patent/CO2024007413A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4433095A1 (en) | 2024-09-25 |
| CL2024001486A1 (es) | 2024-11-29 |
| AU2022390891A1 (en) | 2024-06-06 |
| CO2024007413A2 (es) | 2024-11-18 |
| IL312884A (en) | 2024-07-01 |
| CA3243300A1 (en) | 2023-05-25 |
| MX2024005938A (es) | 2024-08-14 |
| KR20240130157A (ko) | 2024-08-28 |
| TW202330015A (zh) | 2023-08-01 |
| JP2024542212A (ja) | 2024-11-13 |
| WO2023091957A1 (en) | 2023-05-25 |
| CN118574642A (zh) | 2024-08-30 |
| US20230416331A1 (en) | 2023-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39129A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| PE20220563A1 (es) | Conjugados peptidicos de citotoxinas como terapeuticos | |
| PA8557501A1 (es) | Benzamida, heteroarilamida y amidas inversas | |
| ATE297203T1 (de) | Antithrombotische mitteln | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| BR0115411A (pt) | Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares | |
| AR077629A1 (es) | Mimetico de smac | |
| ECSP066653A (es) | Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad | |
| MX2024007312A (es) | Inhibidor doble de pde3/4 heterociclico condensado triciclico y uso de este. | |
| CL2023003327A1 (es) | Inhibidores de la interaccion de menina-mll | |
| DOP2024000146A (es) | Inhibidores de parp7 | |
| CL2025000529A1 (es) | Compuestos derivados de dioxoisoquinolinona, inhibidores de ezh1 y/o ezh2; uso para tratar cáncer. | |
| CL2025001119A1 (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| MX2022011240A (es) | Azálidos de urea inmunomoduladores. | |
| AR127496A1 (es) | Compuestos de cd73 | |
| BR0314352A (pt) | Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6 | |
| PE20220485A1 (es) | Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos | |
| AR125479A1 (es) | Inhibidores de il4i1 y métodos de uso | |
| BR0311491A (pt) | Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero | |
| BRPI0413384A (pt) | inibidores da proteìna farnesil transferase como agentes antitumores | |
| CO2025018006A2 (es) | Formas sólidas de un inhibidor macrocíclico de farnesiltransferasa y formulaciones de estos, y métodos de preparación y uso del compuesto macrocíclico y sus formas sólidas | |
| MX2019004842A (es) | Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. | |
| TR200100611T2 (tr) | İbuprofen ve domperidon içeren farmasötik kompozisyonlar | |
| DK1294732T3 (da) | Ruthenium (II)-forbindelser til anvendelse i cancerterapi | |
| AR124975A1 (es) | Compuestos químicos |